Core Viewpoint - Guangzhou Yijie Medical Technology Co., Ltd. has received NMPA approval for its Yijie Xingyi™ peripheral blood thrombus aspiration catheter, which is designed to remove thrombus from the peripheral vascular system [2]. Group 1: R&D Background - Peripheral arterial thromboembolic diseases primarily include arterial embolism and thrombosis, often presenting acutely, with some cases being subacute or chronic [4]. - Treatment methods for acute lower limb arterial thrombosis include anticoagulation therapy, surgical revascularization, interventional procedures, and in severe cases, amputation [4]. - Advances in technology have led to an increased application of endovascular treatments [4]. Group 2: Disease Overview - Deep vein thrombosis (DVT) is a common and challenging peripheral thromboembolic disease, characterized by blood clot formation in deep veins, leading to blood flow obstruction [6]. - In 2021, there were 1.8 million hospitalized patients with venous thromboembolism (VTE) in China, with a prevalence rate of 127.8 per 100,000 people, making it the third most common vascular disease after ischemic heart disease and stroke [6]. - Major treatment options for DVT include anticoagulation, catheter-directed thrombolysis, percutaneous mechanical thrombectomy (PMT), and surgical thrombectomy [6]. - PMT has gained recognition among clinical experts and is recommended as a first-line surgical treatment for thrombus removal in recent guidelines [6]. Group 3: Product Introduction - Yijie Medical's peripheral thrombus aspiration catheter addresses significant clinical treatment needs and features an innovative adjustable separator to enhance thrombus removal efficiency [7]. - The product consists of an aspiration catheter and accessories, designed for effective thrombus clearance [9]. Group 4: Company Overview - Established in August 2020, Yijie Medical is located in Huangpu District, Guangzhou, and focuses on the R&D, production, and sales of interventional medical devices [13]. - The company has received NMPA registration for 13 products and FDA approval for 2 products, expanding its commercial presence in regions including South America, East Asia, Southeast Asia, Central Asia, and the Middle East [13]. - The company has recently won bids for its neurointerventional products in public medical institutions in Henan Province [15].

迈普医学（301033）重组预案于6月5日晚间出炉。预案显示，公司拟筹划发行股份及支付现金购买广州易介医疗科技有限公司（以下简 称"易介医疗"）100%股权并募集配套资金暨关联交易事项，公司股票自6月6日开市起复牌。迈普医学旨在通过此次交易将生物合成材料技术 由植入领域扩展至介入领域。值得一提的是，此次交易为关联交易，易介医疗系迈普医学实控人袁玉宇旗下资产。此外，易介医疗系一家亏 损企业，2023—2024年净利持续亏损，短时间内，此次并购可能无法为公司带来业绩上的增益。 拟购易介医疗100%股权 针对公司相关问题，北京商报记者致电迈普医学董秘办公室进行采访，不过对方电话未有人接听。 系关联交易 重组预案显示，迈普医学拟通过发行股份及支付现金的方式向泽新医疗等10名交易对方购买易介医疗100%股权。同时，迈普医学拟向公司控 股股东、实际控制人袁玉宇发行股份募集配套资金。本次募集配套资金拟用于支付现金对价、本次交易中介机构费用和交易税费及补充流动 资金等。 迈普医学表示，根据深交所的相关规定，经公司申请，公司股票将于6月6日开市起复牌。 资料显示，易介医疗是一家为脑血管疾病治疗提供微创介入式整体解决方案的高新技 ...

经与会监事认真审议，以记名投票表决方式通过以下决议： 监事会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-034 广州迈普再生医学科技股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司" ）第三 届监事会第九次会议决议于 2025 年 6 月 5 日下午 14：00 以现场方式 在公司会议室召开。本次会议通知已于 2025 年 5 月 30 日以书面的方 式向全体监事和相关与会人员发出。会议应出席监事 3 人，实际出席 会议监事 3 人。本次会议由监事会主席莫梅玲女士召集并主持，公司 董事会秘书龙小燕女士列席了会议。本次会议的召集、召开和表决程 序符合国家有关法律、行政法规及《广州迈普再生医学科技股份有限 公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司符合发行股份及支付现金购买资产并 募集配套资金暨关联交易条件的议案》 公司拟发行股份及支付现金购买广州泽新医疗科技有限公司、广 州易创享投资合伙企业（有限合 ...

迈普医学（301033）(301033.SZ)筹划收购。 5月21日晚间，迈普医学发布公告，公司正在筹划发行股份及支付现金购买广州易介医疗科技有限公司 (简称"易介医疗")不低于51%的股权，并募集配套资金事项，此次交易预计构成重大资产重组，构成关 联交易。 一季度净利保持高速增长 资料显示，目前，迈普医学获得了10个中国医疗器械注册证及5个产品的MDR证书，市场已覆盖全球超 100个国家和地区，销售产品近130万件。 人工硬脑(脊)膜补片、颅颌面修补及固定系统是迈普医疗最主要的收入来源，分别占营业收入的55.88% 及28.69%。公司已与境内外近1000家经销商建立良好的合作关系，产品已进入国内近2000家医院。 近两年来，随着核心产品销量提升，迈普医学业绩持续增长，今年一季度，营业收入、净利润同比增速 分别达28.84%、61.68%。二级市场上，公司股价呈上扬走势，5月21日报收64.13元/股，较2024年2月低 点上涨近2倍。 拟收购易介医疗不低于51%股权 根据公告，迈普医学已与泽新医疗、易创享等主要交易对方签署了意向协议，收购完成后，上市公司将 成为易介医疗控股股东。本次交易的具体方案有待交易 ...

2025年5月15日-18日，东方脑血管病会议2025(OCIN 2025)暨上海市医学会脑卒中分会学术年会在中国上海召开。同时，OCIN 2025牵手世界神经介入大会 (WLNC)联合办会，共同打造全球化脑血管病和神经介入交流的顶级盛宴。 5月17日，"心玮长城·如意双支架研讨会"与"取栓专题国际论坛"于上海国际会议中心成功举办，新产品"长城""如意"及新技术"CATCH级联"亮相本次会 议，通过专题演讲、技术研讨与跨国对话，展现了"中国智造"的创新实力与国际前沿技术的深度碰撞。 精密护航 支撑未来 ——心玮长城·如意双支架研讨会 会议由李天晓教授与史怀璋教授联合致辞启幕。李天晓教授强调医学创新驱动发展，心玮两大突破性产品："长城支架"作为国产首款颅内动脉瘤栓塞辅 助支架，创新适配17系微导管以优化远端小血管治疗；"如意密网"作为国内首个涂层密网支架，拥有聚磷酰胆碱涂层、镍钛球囊设计、以及兼容21小系 统等特点。 史怀璋教授指出，国产神经介入产品历经八年从起步跃升国际赛道：长城支架通过小口径导管精准释放，性能比肩国际品牌；如意密网支架作为国产首款 涂层支架，其涂层、小系统设计超越进口产品。这些突破证明国产器 ...

Core Insights - The company reported a revenue of 2.066 billion yuan for 2024, representing a year-over-year increase of 25.18%, with a net profit of 673 million yuan, up 26.08% [1] - The company’s Q4 2024 revenue was 541 million yuan, a 23.93% increase year-over-year, while Q1 2025 revenue reached 564 million yuan, also reflecting a 23.93% growth [1] Group 1: Business Performance - The electrophysiology business showed steady growth with revenue of 440 million yuan in 2024, a 19.73% increase, and a gross margin of 73.76% [2] - The coronary pathway revenue was 1.054 billion yuan, up 33.3%, with a gross margin of 73.21%, while peripheral intervention revenue reached 351 million yuan, a 37.09% increase [2] - The overall gross margin for the company improved to 72.31%, an increase of 1.04 percentage points, driven by enhanced production efficiency and scale effects [2] Group 2: Market Expansion - Domestic market revenue reached 1.769 billion yuan, a 25.68% increase, with over 200 new hospital admissions in electrophysiology and more than 15,000 three-dimensional surgeries completed [3] - International market revenue was 280 million yuan, a 19.62% increase, with the company’s own brand growing over 45%, particularly in the Middle East, Africa, and Europe [3] - The company made significant progress in product registration and channel development in the CIS region, enhancing its product matrix in PCI and achieving breakthroughs in high-end hospitals in Spain, France, Italy, and Germany [3] Group 3: Research and Development - The company invested 290 million yuan in R&D in 2024, accounting for 14% of its revenue, to strengthen its capabilities in interventional devices [3] - New product launches included pulse ablation catheters and various vascular intervention products, contributing to a robust pipeline for long-term growth [3] Group 4: Profit Forecast - Revenue projections for 2025-2027 are 2.695 billion, 3.398 billion, and 4.279 billion yuan, with year-over-year growth rates of 30.47%, 26.08%, and 25.93% respectively [4] - Expected net profits for the same period are 907 million, 1.156 billion, and 1.453 billion yuan, with growth rates of 34.74%, 27.49%, and 25.68% respectively [4]

智通财经APP讯，心玮医疗-B(06609)发布截至2024年12月31日止年度业绩，该集团取得收益人民币2.78 亿元(单位下同)，同比增加19.6%;研发成本5894万元，同比减少52.4%;母公司拥有人应占亏损1362.2万 元，同比减少85.51%;每股亏损0.36元。 于2024财政年度，本公司取得收入2.78亿元，同比增长19.6%。尽管受批量采购价格影响及市场竞争导 致毛利率下降，本公司税前亏损大幅收窄至1200万元，同比减少88.3%。随着业务规模扩张及成本控制 与增效措施成效显现，销售及分销开支与行政开支的费用率降至49.6%(2023年： 66.2%)。 年内，为适应快速变化的市场环境，本公司持续推动神经介入业务升级，聚焦差异化治疗器械。急性缺 血性脑卒中治疗器械(如颅内取栓支架、远端通路导管、颅内血栓抽吸导管及支撑导管等)销量增长 45.5%。出血性脑卒中治疗器械及其他介入通路器械收入分别增长104.2%及109.4%。 2024年，本公司研发成本为5890万元，以支持多元化神经介入治疗器械在研产品。截至本公告日期，用 于治疗出血性脑卒中的颅内动脉瘤栓塞辅助支架(NMPA创新器械资质)及 ...